Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 25 versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MANNITOL 25 versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
MANNITOL 25% vs OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from intracellular and interstitial spaces into the intravascular compartment. In the kidney, it is filtered but not reabsorbed, increasing tubular fluid osmolarity and promoting water excretion. It also reduces intracranial and intraocular pressure by creating an osmotic gradient.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.
1-2 g/kg (4-8 mL/kg) intravenously as a 25% solution over 30-60 minutes; may repeat every 6-8 hours as needed.
Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 mL of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.
None Documented
None Documented
Terminal elimination half-life: 0.25–1.7 hours; prolonged in renal impairment.
The terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal renal function. This can be prolonged to 6-12 hours in patients with renal impairment, requiring dose adjustment.
Renal: >90% unchanged by glomerular filtration; biliary/fecal: <5%.
Mannitol is excreted primarily by the kidneys via glomerular filtration, with approximately 80% of an administered dose appearing unchanged in urine within 3 hours. Less than 10% undergoes tubular reabsorption; negligible biliary or fecal elimination (<1%).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic